Column1 | Diagnosis | Location | Maximum dimension (cm) | Tmax/M | Tav/M | pO2 #1 (mmHg) | pO2 #2 (mmHg) | PO2 #3 (mmHg) |
|---|
Cat 8a
| SCC | Mandible | 4.41 |
11
| 3.05 | 2.2 | 26 | 2.6 |
Cat 8b
| SCC | Mandible | 4.41 |
11.8
| 3.16 | 24 | 2.8 | 2.6 |
Cat 9a
| SCC | Maxilla | 4.18 |
4.25
| 1.83 | 0.3 | 0.1 | 0.6 |
Cat 9b
| SCC | Maxilla | 4.06 |
5
| 1.73 | 14 | 19 | 20 |
- Cat 8 was treated with Anginex, an anti-vascular peptide, while cat 9 was treated with toceranib, a VEGFR2 inhibitor. 64Cu-ATSM PET/CT and intratumoural fluorescent O2 measurements were performed 7Â days apart, with treatment occurring in the intervening interval. Lower case letter a and b indicates pre- and post-treatment data, respectively. The location of the mass, maximum dimension of the mass, Tmax/M, Tav/M and pO2 in three tumor regions are provided. HNSCC = head and neck squamous cell carcinoma.
